ADVERTISEMENT

India Healthcare Q2 Results Preview - Expect Weakness In India Branded Formulations Growth: Systematix

IPM is expected to grow around 8% during the quarter, with Sun Pharma, Cipla, Lupin, and Mankind Pharma expected to outperform, adds the brokerage.

<div class="paragraphs"><p>Close view of holding capsules. (Photo: freepik)</p></div>
Close view of holding capsules. (Photo: freepik)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More